1593P Real-world data on anemia management in patients with solid tumors and malignant lymphoma in Germany

Anemia is a frequent complication in patients with breast cancer (BC), gastrointestinal tumors (GC), lung (LC) and malignant lymphomas (ML). Guidelines (GL) on anemia management (ESMO, DGHO) provide dedicated algorithms for diagnosis treatment of anemia. GL adherence (GLAD) was analyzed. This retrospective sample analysis representative practices hospitals Germany. Data tumor treatments collected from records (pts) grade ≥ 2 diagnosed between January June 2021. Definition GLAD score (GLAD-D): points (pt) full adherence, 1 pt lack differential iron metabolism. 0 if missing. Treatment (GLAD-T): to recommendation relation diagnosis. indicated red blood cells (RBC) as only therapy or no pts Hb ≥8g/dl. RBC without indication, p.o. substitution under inflammatory conditions (CRP>5mg/l) vitamin B12 folate deficiency substitution. 1046 (311 BC, 371 GC, 260 LC, 104 ML) were 143 centers. Hb-values at 8-10 g/dl 899 (85.9%) pts, 6-8g/dl 135 (12.9%) <6g/dl (1.2%) 12 pts. 456 treated (43.6%), 198 (18.9%) substitution, 106 (10.1%) ESA 60 (5.7%) B12. 60.6% the i.v. 39.4% 37.5% had indication sense restrictive policy recommended by GLs. poor treatment: GLAD-D 310 (29.6%) 168 (16.1%) 568 (54.3%) GLAD-T 270 (25.8%), 466 (44.6%). Higher correlated significantly higher (τB 0.262, p<0.001). Full (2 pt) associated greater increase (p<0.001) 28 days (10.2 vs. 9.7 g/dl) months (10.4 vs 9.9 g/dl). insufficient Germany, especially concerning liberal transfusion diagnostics Pts per Hb-increase.